1. Scrip
  2. >>Business

Roche Could Have The Best Obesity Pill

 
• By Elizabeth Cairns

That is, if very early data in a handful of patients are borne out in later, larger studies.    

Pills and dollars

The data are early both in terms of trial stage and time point, but Roche Holding AG’s newly acquired CT-996 looks like it might be the most effective obesity pill yet. The GLP-1 agonist, which Roche got when it bought Carmot Therapeutics Inc. for $2.7bn in December, looks more effective even than Viking Therapeutics, Inc.’s VK2735 – though this asset is more advanced.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

In Brief: Merck To Invest $1bn In New US Biologics Production

 
• By Sushmita Panda

Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.

Can European Biotech Survive And Thrive In Era Of Instability?

 
• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.